Open-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain Metastases
Clinical trial NCT03463525 · COMPLETED
Trial details
- NCT number
- NCT03463525
- Sponsor
- AstraZeneca
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2018-10-24
- Primary completion
- 2020-03-19
- Enrollment
- 4
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.